Those things are happening too. Here's a summary of sixteen companies' efforts according to
https://www.statnews.com/2020/03/19/an-updated-guide-to-the-...- Gilead Sciences; remdesivir for treatment; currently in phase 3 clinical trials
- Ascletis Pharma; danoprevir/ritonavir for treatment; currently in phase 1 clinical trials
- Moderna Therapeutics; mRNA vaccine; currently in phase 1 clinical trials
- CanSino Biologics; attenuated vaccine; currently in phase 1 clinical trials
- Arcturus Therapeutics; hybrid RNA vaccine; currently preclinical
- BioNTech; mRNA vaccine; currently preclinical
- CureVac; mRNA vaccine; currently preclinical
- Eli Lilly; isolated antibody treatment; currently preclinical
- GlaxoSmithKline; vaccine adjuvants; currently preclinical
- Inovio Pharmaceuticals; DNA-based vaccine; currently preclinical
- Johnson & Johnson; attenuated vaccine; currently preclinical
- Pfizer; assistance with both vaccines and treatments
- Regeneron Pharmaceuticals; engineered antibody treatment; currently preclinical
- Sanofi; hybrid DNA-based attentuated virus vaccine; currently preclinical
- Takeda; isolated antibody treatment; currently preclinical
- Vir Biotechnology; isolated antibody treatment; currently preclinical
Most of these are in very early stages, but I'm optimistic that that speed of development of both treatments and vaccines will exceed the consensus expectations.